AVITA’s RECELL® System trial on DFU patients yields favorable results
Category: #health  By Mateen Dalal  Date: 2019-07-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

AVITA’s RECELL® System trial on DFU patients yields favorable results

The 26-week observational study included 16 subjects at three different hospitals in the UK

Global regenerative medicine company AVITA Medical has recently announced that their open-label study of the latest RECELL® System, conducted on 16 subjects with diabetic foot ulcers (DFUs) who had been unresponsive to standard care treatments, yielded promising results.

Apparently, the RECELL® Autologous Cell Harvesting Device uses a small portion of a patient’s own skin to formulate Spray-On Skin™ Cells at the point-of-care.

Mr. Tawqeer Rashid, Consultant Vascular and Endovascular Surgeon at the Manchester Royal Infirmary, was quoted saying that there was a definite need to find new cures for chronic conditions like DFUs, since they deeply impact the patients’ lives.

Reportedly, Rashid made the announcement at the 11th annual Japanese Society of Limb Salvage & Podiatric Medicine conference held in Japan on June 28 & 29, 2019. He also added that the RECELL® System showed favorable potential in speeding up the healing of DFUs.

Citing reliable sources, the 26-week observational study included 16 subjects at three different hospitals in the UK, including Manchester Royal Infirmary, Northwick Park Hospital and Kings College Hospital. Subjects under observation suffered from chronic DFUs ranging from 5 to 33 sq.cm, with variable depths, with and without infection, inclusive of tendon and bone exposure, that had not been responsive to various standard treatments.

The patients were then treated with the RECELL® System which was applied over the affected area.

Evidently, the study generated encouraging results, including an 83% average wound size reduction in all the patients at the end of the 26th week and 100% recovery in half of the patients with an average period of 14 weeks. The treatment seems to have provided a satisfactory safety profile and excellent patient and physician scores were reported following the study. 

AVITA Medical CEO Michael Perry stated that successful conclusions from the study demonstrate RECELL® System’s versatility and the company is committed towards exploring how their new regenerative technology can be further developed for advance patient care. 

Source credit: https://www.avitamedical.com/uploads/pdf/PR-20190701.pdf

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...